Selarsdi
Active Ingredient(s): Ustekinumab-aeknFDA Approved: * April 16, 2024
Pharm Company: * ALVOTECH USA INC
Category: Immunosuppressive
Ustekinumab, sold under the brand name Stelara is a monoclonal antibody medication developed by Janssen Pharmaceuticals, for the treatment of Crohn's disease, ulcerative colitis, plaque psoriasis and psoriatic arthritis,[5] targeting both IL-12 and IL-23.[6] Ustekinumab is approved to treat Crohn's disease in the United States, Israel, Australia, and the European Union (EU), and ulcerative colitis in the US, and in the EU to patients who have not responded to m... [wikipedia]
* May have multiple approval dates, manufacturers, or labelers.Dosage List
Selarsdi 45 mg/.5ml Subcutaneous Injection, Solution
NDC: 51759-505
Labeler:
Teva Pharmaceuticals USA, Inc.
Selarsdi 90 mg/ml Subcutaneous Injection, Solution
NDC: 51759-607
Labeler:
Teva Pharmaceuticals USA, Inc.
Selarsdi 130 mg/26ml Intravenous Injection, Solution
NDC: 51759-708
Labeler:
Teva Pharmaceuticals USA, Inc.